AI’s Great Potential for Personalized Medicine
AI can help medicine navigate an enormous range of paths. Whether researchers are examining molecular candidates, genetic information, imaging, biomarkers or treatment histories, the possible combinations quickly exceed what any individual clinician or research team can explore. AI is well suited to identifying promising areas for deeper investigation, helping experts narrow the search before applying established clinical, scientific and computational methods.
However, narrowing the field is not the same as making a discovery. At least for now, AI is more likely to find useful paths through information we already possess than to generate truly novel biological insight on its own. Human judgment remains essential to frame the problem, validate the evidence, and determine whether an apparent answer makes biological and clinical sense.
This is why the most visible early gains may come not from AI-created drugs but from diagnosis, treatment selection and monitoring. These uses can help clinicians interpret information across biomarkers, medical records, imaging and a patient’s history. They can also support more precise patient segmentation, which is the practical path toward individualized medicine. The ideal is treatment optimized for one person; the near-term reality will often be increasingly refining groups of patients whose conditions, risks and likely responses are more similar than today’s broad categories.
The value of this approach is to strengthen, not replace, clinical judgement. AI can give clinicians a more complete picture by bringing together relevant information that may otherwise sit in separate systems or be difficult to assess at once. A physician can see, listen and draw on experience, but some symptoms have multiple possible causes. Integrating relevant data sources can make important patterns easier to recognize and help the care team ask better questions.
Healthcare Must Prioritize the Safe Deployment of AI
Still, healthcare leaders should be skeptical of claims that AI will solve every disease within a few years. Algorithmic progress may be fast. Deployment is not.
Clinical evidence, regulatory review, reimbursement, privacy protections, cybersecurity and public acceptance all shape whether a healthcare innovation reaches patients. These constraints exist for good reasons. A model that performs well in a controlled setting is not automatically ready for diverse patient populations or high-stakes clinical decisions. For drug development in particular, AI may accelerate discovery and optimization, but it cannot eliminate the need for rigorous validation.
Among these considerations, privacy and governance are foundational. Personalized care requires sensitive information such as health records, biomarkers, genetics, imaging and, often, longitudinal data. Without strong protections for confidentiality and appropriate governance, organizations will not earn the trust required to build and use the data resources that more tailored care depends on.
READ MORE: Harness the power of data and AI to transform healthcare delivery.
Healthcare also must address the ethical consequences of drawing conclusions across demographic groups. A technically accurate correlation can still be harmful if it is used without context, transparency and safeguards.
Health systems should therefore build capabilities before chasing every new tool. That means treating data quality, privacy, security and compute infrastructure as strategic concerns rather than background IT functions.
It also means looking beyond generative AI. Physical AI — sensors, diagnostics, robotics and other systems that connect algorithms to the physical world — may have a particularly meaningful role in monitoring, analysis and earlier detection.
The winners will not necessarily be the organizations that adopt first. They will be the ones that develop a credible roadmap of identifying problems that matter to patients and clinicians, testing solutions carefully, measuring outcomes, and expanding only when the value is clear.
In innovation, timing is often more important than the invention itself. Move too early, and a promising technology may fail because the evidence, economics or trust are not ready. Move too late, and patients and care teams lose the benefits of capabilities that could have made a real difference.
The task for healthcare leaders is to hold both truths at once: Invest in the future of AI-enabled medicine but insist that progress earns its place in care.
